IGI Logo
Toggle Navigation
News
Hindi
Hindi News
Top News
Screeners
Stocks
Stocks Screener
Stock
News
Stock Market Home Page
Stock News
Industry News
Economy News
Stock on the move
Expert Views
Research Reports
Company Result
Comp Info And Fundamentals
Company Profile
Equity
Financial Ratios
Results
Balance Sheet
Profit And Loss
Cash Flow
Share Holding
Derivatives (F&O)
Get Quotes
Market Watch
Top Gainers
Top Losers
Top Traded Quantity
Top Traded Value
Most Active Puts
Derivatives (F&O)
Most Active Calls
Put Call Ratio
Highest In Premium
Daily Settlement Price
FII and DII Statistics
Open Interest: Highest In OI
Open Interest: Lowest In OI
Derivatives (F&O)
Open Interest: Increase in OI Increase in Price
Open Interest: Decline in OI Decrease in Price
Derivative Watch
Derivatives Dashboard
Historical Data
List of Underlyings & Underlying Info
Derivative Watch
Derivatives Dashboard
Market Reports
Top Gainers
Top Losers
Monthly High/Low
52 Week High
52 Week Low
Market Cap Gainers
Market Cap Losers
PE Ratio
>More Market Reports
IPO
News
IPO News
IPO Issue Reports
Commodity
Commodity Market
Commodity Home Page
Commodity News
Commodity Reports
Market Details
Get Quotes
Top Gainers
Top Losers
Top Volume
Top Value
Top Gainers Spot Market
Top Losers Spot Market
High & Low
Commodity Indices
Technical Analysis
Advance Declines
High & Low
Highest In OI
Lowest OI
Increase In Open Interest(%)
Descrease In Open Interest(%)
Currency
News
Currency News
Economy News
Currency Reports
Mutual Fund
News
Mutual Fund Home Page
Mutual Fund News
Mutual Fund Details
Mutual Fund Home Page
Compare Scheme
Scheme Profile
Mutual fund Investment
Mutual Fund Share Holding
Mutual Fund Statistics
Mutual fund Gainers
Mutual fund Losers
Biggest Schemes
Best Performers
Latest Dividend Details
Tools
Multi Scheme Comparison Tool
Dividend Details
Performance Map
Mutual fund Investment
Mutual fund Share Holding
Mutual Fund Search Category Rankings
Widgets
Stock Widgets
Watchlist
Heatmap
Mutual Fund Widgets
Watchlist
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
Wealth
World
Tips
Intraday Tips
Market Outlook
Stock Tips
Commodity Tips
Currency Tips
Reports
Short Term Investment Opportunities
Long Term Investment Opportunities
Sector Analysis
Commodity Reports
Currency Reports
Mutual Fund Analysis
Podcast
Videos
Videos Category
Business Videos
Budget Videos
News And Politics
Entertainment Videos
Sports Videos
Lifestyle And Fashion Videos
Global News Videos
Calculators
EMI Calculator
SIP Calculator
SWP Calculator
GST Calculator
FD Calculator
RD Calculator
More
Budget 2024
Astrology
Women
Politics
Entertainment
Car&Bike
Gadgets
Lifestyle
Sports
Health
Fashion
Diwali Reports
Diwali Expert Reports
News
Astrology
Beyond Market Car
Beyond Market Entertainment
Beyond Market Fashion
Beyond Market Gadgets
Beyond Market Health
Beyond Market India
Beyond Market Life Style
Beyond Market Sports
Broking Firm Views
Broking Firm Views - Long Term Report
Broking Firm Views - Sector Report
Broking Firm Views - Short Term Report
Budget 2024 Sector Reports
Budget Bites
Budget Economic Servey
Budget Expert Views
Budget Industry
Budget News
Budget Wishlist
Commodities
Commodities Reports
Commodity Top News
Company News
Company Result
Currency News
Currency Report
Currency Top News
Diwali Expert Views
Diwali Market Outlook
Diwali Report
Diwali Technical Report
Economy News
Expert View Institution
Expert Views
Industry News
IPO Analysis
IPO More News
IPO Reports
IPO Top News
Market Outlook
Mutual Fund Analysis
Mutual Fund Expert Views
Mutual Fund More News
Mutual Fund Top News
Podcast - Market Ki Awaaz
Special Event Expert Views
Special Event Reports
Startup
Startup Expections
Startup Speak
Stock Market
Stock On The Move
Top News
Top Stories
Videos
Videos Business
Videos Entertainment
Videos Global News
Videos Lifestyle And Fashion
Videos News And Politics
Videos Sports
Wealth
Women
World Market More News
World Top News
Search
Akums Drugs & Pharmaceuticals is currently trading at its upper limit of Rs. 580.95, up by 27.65 points or 5.00% from its previous closing of Rs. 553.30 on the BSE. The scrip opened at Rs. 536.15 and has touched a high and low of Rs. 580.95 and Rs. 527.00 respectively. So far 109506 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 527.00 on 19-Nov-2024. Last one...
Akums Drugs hits upper limit on entering into exclusive master sales agreement with Caregen
North America/Russia/ROW drive earnings Limited visibility to grow beyond the g-Revlimid opportunity * Dr Reddy’s Lab (DRRD) delivered in-line 2QFY25 performance. DRRD exhibited robust YoY growth in North America (NA), Russia, and ROW markets and a healthy scale-up in the pharmaceutical services and active ingredients segment. This was offset by moderate YoY growth in the Europe/CIS business. * Higher volume growth and new launches have been the key factors driving su...
Neutral Dr Reddy`s Laboratories Ltd For Target Rs.1,390 By Motilal Oswal Financial Services Ltd
Superior execution in consumer wellness/exports drives beat on 2Q estimates Integration of BSV under way * Mankind Pharma (MANKIND) delivered better-than-expected 2QFY25 performance, fueled by a strong revival in growth of the consumer business and continued growth momentum in the exports business. * MANKIND continues to deliver a better growth rate than the industry in the Rx-prescription business, supported by a niche portfolio and superior execution in chronic therapies....
Buy Mankind Pharma Ltd For Target Rs.3,140 By Motilal Oswal Financial Services Ltd
Shilpa Medicare is currently trading at Rs. 896.50, up by 33.10 points or 3.83% from its previous closing of Rs. 863.40 on the BSE. The scrip opened at Rs. 885.40 and has touched a high and low of Rs. 917.20 and Rs. 881.60 respectively. So far 23504 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 959.95 on 18-Sep-2024 and a 52 week low of Rs. 313.55 on 10-Jan-2024. Last one week high and low of the scrip stood a...
Shilpa Medicare soars as its arm gets CEP from EDQM for API Octreotide
Astrazeneca Pharma India is currently trading at Rs. 6518.15, up by 120.50 points or 1.88% from its previous closing of Rs. 6397.65 on the BSE. The scrip opened at Rs. 6450.05 and has touched a high and low of Rs. 6588.35 and Rs. 6450.05 respectively. So far 543 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 8139.85 on 30-Sep-2024 and a 52 week low of Rs. 4050.15 on 21-Mar-2024. Last one week high and low of th...
AstraZeneca Pharma surges on planning to launch Breztri Aerosphere in January 2025
FDC is currently trading at Rs. 489.95, down by 6.45 points or 1.30% from its previous closing of Rs. 496.40 on the BSE. The scrip opened at Rs. 490.25 and has touched a high and low of Rs. 492.55 and Rs. 480.80 respectively. So far 7209 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 659.00 on 12-Sep-2024 and a 52 week low of Rs. 375.65 on 21-Dec-2023. Last one week high and low of the scrip stood at Rs. 527.00...
FDC falls on the bourses
Dr. Reddy's Laboratories is currently trading at Rs. 1188.85, down by 37.20 points or 3.03% from its previous closing of Rs. 1226.05 on the BSE. The scrip opened at Rs. 1195.60 and has touched a high and low of Rs. 1221.00 and Rs. 1171.00 respectively. So far 40061 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1420.20 on 21-Aug-2024 and a 52 week low of Rs. 1074.35 on 11-Dec-2023. Last one week high and lo...
Dr. Reddy's Laboratories declines on the BSE
Blue Jet Healthcare is currently trading at Rs. 531.40, up by 2.60 points or 0.49% from its previous closing of Rs. 528.80 on the BSE. The scrip opened at Rs. 528.80 and has touched a high and low of Rs. 538.00 and Rs. 519.05 respectively. So far 3744 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 567.90 on 07-Nov-2024 and a 52 week low of Rs. 319.40 on 12-Dec-2023. Last one week high and low of the scrip stood...
Blue Jet Healthcare moves up on getting consent to start manufacturing at Mahad unit
Lack of specific skills and talents has been found to be the biggest obstacle for pharmaceutical companies in their digital transformation journey, according to a new report. Large and medium-sized companies see a lack of specific skills and talents as more of a concern than smaller ones, according to a report by GlobalData. The rapid pace of technological advancement has outstripped the ability of traditional training programs to keep up, creating a significant skills gap. Withou...
Global pharma sector stares at lack of talent, specific skills
In-line 2Q; Future growth drivers intact Aurobindo’s (ARBP) 2QFY25 results were broadly in-line with our expectations. Revenue/EBITDA/PAT grew 8%/12%/8% YoY, and margins expanded by 65 bps YoY. The US segment, which accounts for 45% of sales, grew by 4% YoY, marred by supply chain challenges – this should ease as production gets streamlined. Europe reported robust 19% YoY grow driven by strong performance across key markets. Growth markets grew 44% YoY and API segments reported...
Buy Aurobindo Pharma Ltd For Target Rs.1,755 By JM Financial Services
Generic/currency headwinds in biologics drag down earnings * Currency headwinds in the biologics segment, pricing challenges, and a planned shutdown in the generics segment affected the overall performance of BIOS in 2QFY25. * Despite these challenges, BIOS delivered improved profitability QoQ thanks to a strong revival in its Syngene business. It also continued to gain decent market share by volume in its key biosimilars in the US and EU. New launches, including liraglutide ...
Neutral Biocon Ltd For Target Rs.300 By Motilal Oswal Financial Services Ltd
Cipla Q2FY25 earnings were in line with our expectations on all fronts, with the reported revenue of INR 70,510mn (+5.6% YoY/+5.3% QoQ) driven by growth across all the focused geographies. EBITDA reported at INR 18,856mn (+8.8% YoY/+9.9% QoQ) with the highest ever quarterly margin of 26.7% (+78bps YoY and +111bps QoQ). Adj. PAT was reported at INR 13,025mn with a growth of 15.2% YoY and 10.6% QoQ. The management expects the launch of Advair by mid-FY26, while Abraxane’s release depends ...
Buy Cipla Ltd For Target Rs. 1,543 By Choice Broking Ltd
Industry headwinds hurt performance of generic medicines * Glaxo Pharma (GLXO) delivered better-than-expected 2QFY25 performance. The robust growth in the specialty and pediatric vaccine segments was offset by headwinds in the generic medicine segment. * We raise our estimates by 4%/5%/4% for FY25/FY26/FY27 to factor in: 1) new launches in the oncology segment, b) superior show in the specialty segment, and c) better operating leverage. We value GLXO at 46x 12M forward earning...
Neutral GlaxoSmithKline Pharmaceuticals Ltd For Target Rs.2,800 By Motilal Oswal Financial Services Ltd
Dr. Reddy’s quarterly earnings were above our expectations on the revenue front but lower on earnings. On the revenue front, DRRD reported the highest-ever quarterly revenue of INR 80,382mn, with a robust YoY growth of 16.5% and 4.4% QoQ, the increase was mainly driven by growth in the global generic business. EBITDA reported at INR 20,765mn (+3.4% YoY and -2.5%QoQ) and the margin saw a decline of 326bps YoY and 184bps QoQ to 25.8% on account of change in the mix and one-time acquisitio...
Hold Dr. Reddy`s Laboratories Ltd For Target Rs. 1,449 By Choice Broking Ltd
Sun Pharma’s Q2FY25 earnings came in slightly below expectations. Revenue reached INR 132.9 bn, reflecting a 9% YoY and 5% QoQ growth, driven primarily by robust performance in the US formulations segment. EBITDA rose significantly by 23.9% YoY and 9.2% QoQ to INR 39.4 bn, with margins expanding by 356 bps YoY and 112 bps QoQ to 29.6%. Adjusted PAT increased 28% YoY and 7.2% QoQ to INR 30.4 bn. The company aims for a goof topline growth this year, alongside a planned increase in R&D...
Buy Sun Pharmaceutical Industries Ltd For Target Rs. 2,036 By Choice Broking Ltd
Laurus Labs Q2FY25 results were below our estimates, the company reported a top-line of INR 12,237mn (flat YoY and +2.4.0% QoQ) driven by sustained demand in the CDMO business. EBITDA was reported at INR 1,783mn (-5.1% YoY and +4.2% QoQ) and margin at 14.6% showing a marginal decline of 77bps YoY and marginal improvement of 25bps sequentially. The margin was impacted due to lower asset utilization and dilution from the growth projects. The company is prioritizing efforts to improve its operat...
Buy Laurus Labs Ltd For Target Rs.531 By Choice Broking Ltd
2Q in-line; speed breaker ahead for growth in earnings * Cipla Ltd (CIPLA)’s 2QFY25 operational performance was in line with expectations. This was the fifth consecutive quarter of slowdown in YoY growth in revenue. The superior performance in SAGA/emerging market was offset by reduced YoY growth in domestic formulation (DF)/US. * We reduce our earnings estimate by 3%/4%/3% for FY25/FY26/FY27 to factor in: a) lower sales of Lanreotide on production modifications; b) unfa...
Neutral Cipla Ltd For Target Rs.1,420 By Motilal Oswal Financial Services Ltd
Lupin reported revenue at INR 56,727mn increased by 12.6% YoY and 1.3% QoQ, driven by strong performance in India formulation business and 40% of US revenue coming from the complex generics. EBITDA at INR 13,083mn showed robust growth of 41.7% YoY and 1.7% QoQ, with a margin of 23.6%, expanding by 541bps YoY and 147bps QoQ. The improvement in EBITDA margin was driven by the change in the product mix and cost of raw material procurement coming down. Adj. PAT at INR 8,526mn saw a significant im...
Hold Lupin Ltd For Target Rs. 2,383 By Choice Broking Ltd
Indian drugmaker Zydus Lifesciences reported a 14% rise in second-quarter profit on Tuesday, helped by strong demand for generic drugs in its key United States and Indian markets. The company's consolidated net profit rose to 9.11 billion rupees ($107.93 million), in line with analysts' average estimate of 9.13 billion rupees, as per data compiled by LSEG. Its total revenue climbed 20% to 52.37 billion rupees, boosted by a nearly 30% growth in its U.S. market and a 10% climb in ...
India`s Zydus Life posts Q2 profit rise on steady US demand
Alembic is currently trading at Rs. 138.00, up by 6.05 points or 4.59% from its previous closing of Rs. 131.95 on the BSE. The scrip opened at Rs. 135.60 and has touched a high and low of Rs. 139.25 and Rs. 135.45 respectively. So far 26955 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 169.00 on 23-Aug-2024 and a 52 week low of Rs. 78.00 on 10-Nov-2023. Last one week high and low of the scrip stood at Rs. 139....
Alembic trades higher on reporting 50% rise in Q2 consolidated net profit
India/US drive 2QFY25 performance while Brazil drags Scales new high at gross margin levels * Torrent Pharma (TRP) delivered a miss on earnings due to the reduced offtake of insulin and currency headwinds related to the Brazilian business. TRP continues to outperform in the branded markets of India (DF) and Brazil. The US generics business is yet to pick up scale despite regulatory compliance in place. * We reduce our earnings estimate by 5%/3% for FY25/FY26 to factor in: a...
Neutral Torrent Pharmaceuticals Ltd For Target Rs.3,430 By Motilal Oswal Financial Services Ltd
Solid quarter; success story to continue JB Pharma (JBCP) reported solid results for 2QFY25, with Revenue/EBITDA/PAT growing 13.5%/11%/16% YoY respectively. The India segment led the performance, posting a 22% YoY growth (in line), while export formulations grew by 14% YoY (5% beat). However, both the CDMO and API segments saw decline of 17%/18% YoY respectively. Management guided for a recovery in the CDMO segment in 2HFY25 (20%+ growth) as some sales got deferred to 3Q. Domestic business...
Buy J.B. Chemicals & Pharmaceuticals Ltd For Target Rs. 2,277 By JM Financial Services
Lupin is currently trading at Rs. 2110.75, up by 0.20 points or 0.01% from its previous closing of Rs. 2110.55 on the BSE. The scrip opened at Rs. 2144.00 and has touched a high and low of Rs. 2154.00 and Rs. 2080.00 respectively. So far 115331 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1153.55 on 13-Nov-2023. Last one week high and low of the scrip stood at R...
Lupin inches up on reporting 74% rise in Q2 consolidated net profit
Drugmaker Abbott India reported a rise in second-quarter profit on Thursday, helped by strong demand for its gastrointestinal and anti-infective medications. The company, which makes the antacid Digene, reported a profit of 3.59 billion rupees ($42.6 million) for the quarter ended Sept. 30, up nearly 15% from last year. Revenue from operations climbed 9.3% to 16.33 billion rupees. For further highlights, click KEY CONTEXT Drugmakers such as Abbott India and rival GlaxoSmithKlin...
Abbott India posts Q2 profit rise on strong demand, price hikes
New initiatives to help avoid Revlimid cliff DRRD delivered a strong performance with Revenue/EBITDA/PAT growing 17%/11%/-8% YoY ahead of JMFe and street expectations. US business (8% beat) was led by gRevlimid ramp-up, albeit softer QoQ, was the primary driver. Complex launches and biosimilars will sustain momentum in this business over the medium term. NRT acquisition will reflect from 3Q further improving core margins. India business (in line) improvement was visible with around 9-10% e...
Buy Dr Reddys Laboratories Ltd For Target Rs.1,655 By JM Financial Services
Indian drugmaker Alembic Pharmaceuticals reported a smaller-than-expected rise in second-quarter profit on Thursday, hurt by a slowdown in the U.S. market amid pricing pressure. The company's consolidated profit rose 12% to 1.53 billion rupees ($18.1 million) in the quarter ended Sept. 30, but fell short of the analysts' expectation of 1.55 billion rupees, per estimates compiled by LSEG. Revenue from operations, which rose 3.3% to 16.48 billion rupees, also missed analysts' ...
Indian drugmaker Alembic Pharma misses Q2 profit view as US sales growth slows
Kwality Pharmaceuticals is currently trading at Rs. 941.05, up by 44.80 points or 5.00% from its previous closing of Rs. 896.25 on the BSE. The scrip opened at Rs. 914.00 and has touched a high and low of Rs. 941.05 and Rs. 860.00 respectively. So far 18908 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 961.15 on 04-Nov-2024 and a 52 week low of Rs. 331.10 on 07-Nov-2023. Last one week high and low of the scri...
Kwality Pharmaceuticals zooms on getting nod for Leuprorelin Acetate 11.25 mg vial powder & solvent for injectable suspension
Dr. Reddy's Laboratories is currently trading at Rs. 1300.55, up by 28.00 points or 2.20% from its previous closing of Rs. 1272.55 on the BSE. The scrip opened at Rs. 1272.25 and has touched a high and low of Rs. 1322.00 and Rs. 1251.50 respectively. So far 110555 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1420.20 on 21-Aug-2024 and a 52 week low of Rs. 1,064.52 on 06-Nov-2023. Last one week high and lo...
Dr. Reddy`s Laboratories jumps despite reporting 9% fall in Q2 consolidated net profit
Drugmaker Granules India reported a 4.8% fall in its second-quarter profit on Wednesday, dragged by a slow demand in the North American and European markets. Consolidated profit fell to 972.3 million rupees ($11.54 million) for the quarter ended Sept. 30, from 1.02 billion rupees a year earlier. Granules, which generates 66% of its revenue from North America and 19% from Europe, posted an 18.7% fall in its revenue from operations. For further earnings highlights, (click here) KEY ...
Granules India Q2 profit falls on weak demand in North America, Europe
Gland Pharma is currently trading at Rs. 1814.85, up by 205.00 points or 12.73% from its previous closing of Rs. 1609.85 on the BSE. The scrip opened at Rs. 1600.00 and has touched a high and low of Rs. 1824.20 and Rs. 1600.00 respectively. So far 60279 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2220.95 on 06-Aug-2024 and a 52 week low of Rs. 1503.70 on 06-Nov-2023. Last one week high and low of the scrip s...
Gland Pharma zooms despite reporting 16% fall in Q2 consolidated net profit
Venus Remedies is currently trading at Rs. 311.50, up by 0.75 points or 0.24% from its previous closing of Rs. 310.75 on the BSE. The scrip opened at Rs. 311.55 and has touched a high and low of Rs. 315.20 and Rs. 309.05 respectively. So far 4581 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 260.00 on 06-Nov-2023. Last one week high and low of the scrip stood at ...
Venus Remedies surges on securing Malaysian PIC/S GMP approval for pre-filled syringe facility
Biocon is currently trading at Rs. 307.50, down by 10.40 points or 3.27% from its previous closing of Rs. 317.90 on the BSE. The scrip opened at Rs. 317.05 and has touched a high and low of Rs. 317.05 and Rs. 307.50 respectively. So far 43440 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 395.65 on 17-Sep-2024 and a 52 week low of Rs. 222.55 on 10-Nov-2023. Last one week high and low of the scrip stood at Rs. 3...
Biocon trades lower on reporting 84% fall in Q2 consolidated net profit
Operating performance above est.; FY25 guidance intact * Piramal Pharma (PIRPHARM) delivered better-than-expected operational performance in 2QFY25 fueled by superior traction in the CDMO segment (59% of sales). Following earnings deterioration in FY23/FY24, PIRPHARM is exhibiting healthy recovery in 1HFY25. Considering the advancement in clinical development of certain CDMO projects, the company is investing USD80m to double its sterile fill-finish capacities at the Lexington site. * ...
Buy Piramal Pharma Ltd For Target Rs. 310 By Motilal Oswal Financial Services Ltd
Sun Pharmaceuticals, India's largest drugmaker by revenue, reported second-quarter profit above analysts' estimates on Monday, aided by higher demand for its specialty drugs that are used to treat uncommon medical conditions. The Mumbai-based firm's net profit rose 28% to 30.40 billion rupees (nearly $362 million) for the three months ended Sept. 30, beating analysts' estimate of 28.87 billion rupees, according to data compiled by LSEG. The company's high-margin glob...
India's Sun Pharma beats Q2 profit view on higher demand for specialty drugs
Dr. Reddy's Laboratories Ltd * Technical indicators visualize weaker setup in the pharma space, where DRREDDY reflects the same weakness. * Stock has recently closed below its support and important moving average (100EMA). * It has also faced multiple resistance at 50% Fibonacci retracement of its primary corrective trend. * In continuation of the breakdown from the rising trend line, bias remains negative. * Traders are recommended to comply with the trend in the mentioned...
Stock of the day : Dr. Reddy's Laboratories Ltd For Target Rs. 236 - Religare Broking
Divis Laboratory Ltd * The Stock has given breakout of a Rounding formation on the longer term charts. * The stock has given three year Breakout with increase in volumes post breakout. Positive RSI Crossover is seen on the weekly charts. * Stock is well placed above all the important moving averages. * Therefore, investor can buy the stock at 5720 and on dips to Rs 5470 for a target of Rs 7200 with a strict stop loss placed below Rs 5140 Buy Divis Laboratory ...
Diwali Technical Pick 2024 : Buy Divis Laboratory Ltd For Target Rs. 5140 - Nirmal Bang Ltd
Piramal Pharma is currently trading at Rs. 246.00, up by 29.30 points or 13.52% from its previous closing of Rs. 216.70 on the BSE. The scrip opened at Rs. 227.90 and has touched a high and low of Rs. 246.70 and Rs. 224.05 respectively. So far 1237407 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 248.50 on 24-Sep-2024 and a 52 week low of Rs. 87.55 on 26-Oct-2023. Last one week high and low of the scrip stood...
Piramal Pharma zooms on reporting over 4-fold jump in Q2 consolidated net profit
Sun Pharmaceutical Industries Ltd * Selling pressure is evident throughout the pharma space and SUNPHARMA trades parallel to same tone. * Recently the stock witnessed breakdown below its rising trend line after a distribution pattern or range consolidation. * Momentum indicators suggest the tone is likely to continue with negative bias & follow-on selling pressure could mount. * Traders are recommended to play the momentum with using PUTs in the mentioned range. ...
Stock of the day : Sun Pharmaceutical Industries Ltd For Target Rs. 46 - Religare Broking
Mankind Pharma on Wednesday said it has completed the acquisition of Bharat Serums and Vaccines Limited (BSV) for Rs 13,768 crore. The acquisition will position Mankind Pharma as a market leader in the Indian women's health and fertility drug market, alongside access to other high entry barrier products in critical care segment with established complex R&D tech platforms, it said in a statement. Their established specialty R&D tech platforms with complex portfo...
Mankind Pharma completes acquisition of BSV for Rs 13,768 crore
Zydus Lifesciences is currently trading at Rs. 1015.00, up by 26.80 points or 2.71% from its previous closing of Rs. 988.20 on the BSE. The scrip opened at Rs. 981.05 and has touched a high and low of Rs. 1016.35 and Rs. 981.05 respectively. So far 33456 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip s...
Zydus Lifesciences jumps on getting in principle acceptability from WHO for ZyVac TCV
Alembic Pharmaceuticals is currently trading at Rs. 1177.95, up by 18.20 points or 1.57% from its previous closing of Rs. 1159.75 on the BSE. The scrip opened at Rs. 1160.05 and has touched a high and low of Rs. 1186.00 and Rs. 1160.05 respectively. So far 1003 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1296.15 on 09-Oct-2024 and a 52 week low of Rs. 707.50 on 31-Oct-2023. Last one week high and low of the ...
Alembic Pharma soars on getting USFDA approval for Diltiazem Hydrochloride Extended-Release Capsules
Akums Drugs & Pharmaceuticals is currently trading at Rs. 915.00, up by 0.25 points or 0.03% from its previous closing of Rs. 914.75 on the BSE. The scrip opened at Rs. 896.00 and has touched a high and low of Rs. 935.00 and Rs. 896.00 respectively. So far 17573 shares were traded on the counter. The BSE group 'B' stock of face value Rs. 2 has touched a 52 week high of Rs. 1174.85 on 20-Aug-2024 and a 52 week low of Rs. 724.50 on 06-Aug-2024. Last one week high and low of...
Akums Drugs and Pharmaceuticals inches up on entering into MoU with Government of Republic of Zambia
Zydus Lifesciences is currently trading at Rs. 1022.85, up by 1.95 points or 0.19% from its previous closing of Rs. 1020.90 on the BSE. The scrip opened at Rs. 1025.05 and has touched a high and low of Rs. 1028.00 and Rs. 1013.95 respectively. So far 4727 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1323.90 on 09-Aug-2024 and a 52 week low of Rs. 567.85 on 26-Oct-2023. Last one week high and low of the scrip ...
Zydus Lifesciences inches up on getting USFDA`s approval for Fludrocortisone Acetate Tablets
India saw cumulative overall exports at $393.22 billion in the April-September period, a growth of 4.86 per cent as compared to $375 billion in the same period last year, the government said on Wednesday. The cumulative value of merchandise exports was $213.22 billion in the first six months of the current fiscal, as compared to $211.08 billion during April-September 2023, registering a positive growth of 1.02 per cent. Services exports are estimated to grow by 9.81 per cent during ...
India sees 4.8 pc overall exports growth in first half of FY25
Lupin is currently trading at Rs. 2248.00, up by 4.85 points or 0.22% from its previous closing of Rs. 2243.15 on the BSE. The scrip opened at Rs. 2234.15 and has touched a high and low of Rs. 2272.15 and Rs. 2234.15 respectively. So far 11302 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2312.00 on 05-Sep-2024 and a 52 week low of Rs. 1113.00 on 31-Oct-2023. Last one week high and low of the scrip stood at Rs...
Lupin inches up on launching first generic version of Pred Forte in United States
The healthcare and pharma sector saw an overall 64 deals, valued at $2.8 billion in Q3 of 2024, marking the sector's highest quarterly volumes in three years, according to a report on Tuesday. The report by Grant Thornton Bharat showed that mergers and acquisitions, and private equity deal volumes increased significantly, with 59 deals worth $2.2 billion, the highest since Q4 2021. However, Q3 2024 saw a 47 per cent decline in deal values compared to Q2 2024. The decline wa...
Indian healthcare, pharma sector sees highest quarterly deal volumes in 3 years
Glenmark Pharmaceuticals Ltd * Pharma index has been maintaining its positive tone and Glenmark is trading in sync. * It has witnessed a fresh breakout above its rising trend line indicating continuation of trend. * Technical indicators and volumes addition suggests the trend likely to continue with certainty of further follow-on * Traders are recommended to participate in the move with positive bias within the said range. Buy Glenmark Pharmaceutica...
Stock of the day : Glenmark Pharmaceuticals Ltd For Target Rs. 1944 - Religare Broking
The Indian pharma market grew 5.1 per cent (year-on-year) in September, led by cardiac, dermal and anti-diabetic therapies, a report showed on Monday. For the 12 months ending in September, the industry grew 7.7 per cent YoY, led by price growth and new launches. However, volume growth was moderate at 0.8 per cent (on-year) last month, according to the report by Motilal Oswal Financial Services Ltd. Acute therapies grew at a modest rate of 3 per cent YoY while chronic therapies gr...
Indian pharma market grows 5.1 pc in September
Load More
